Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 2Unknown 2Recruiting 2Active not recruiting 2Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Ovarian Neoplasms 3Prostatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Microsatellite-stable Colorectal Cancer 1Melanoma 1Lymphoma, B-Cell 1Lung Neoplasms 1Glioblastoma 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Advanced Renal Cell Carcinoma 1Adenocarcinoma of Lung 1

Interventions

Rituximab 2zanubrutinib 1tazemetostat 1prednylidene 1obinutuzumab 1deltacortene 1Vincristine 1Prednisone 1Nivolumab 1Doxorubicin 1Cyclophosphamide 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Lymphoma, B-Cell × Nivolumab × Clear all
NCT03704714 2022-08-15

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Northwestern University

Phase 1/2 Suspended
30 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡